publication venue for
- Successful Renal Denervation Decreases the Platelet Activation Status in Hypertensive Patients.. 116:202-210. 2020
- The Choice of Targets and Ligands for Site-Specific Delivery of Nanomedicine to Atherosclerosis 2020
- Inhibition of heat shock protein 70 blocks the development of cardiac hypertrophy by modulating the phosphorylation of histone deacetylase 2. 115:1850-1860. 2019
- New opportunities for targeting redox dysregulation in cardiovascular disease. 116. 2019
- Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage and dysfunction in salt-sensitive hypertension.. 115:776-787. 2019
- Platelets in cardiac ischaemia/reperfusion injury: a promising therapeutic target. 115:1178-1188. 2019
- The haematopoietic stem cell niche: A new player in cardiovascular disease?. 115:277-291. 2019
- The polarity protein Scrib limits atherosclerosis development in mice. 115:1963-1974. 2019
- Increased collagen within the transverse tubules in human heart failure. 113:879-891. 2017
- B-cell-specific depletion of tumour necrosis factor alpha inhibits atherosclerosis development and plaque vulnerability to rupture by reducing cell death and inflammation. 111:385-397. 2016
- MicroRNA-153 targeting of KCNQ4 contributes to vascular dysfunction in hypertension. 112:581-589. 2016
- Scrib:Rac1 interactions are required for the morphogenesis of the ventricular myocardium. 104:103-115. 2014
- Circulating microparticles generate and transport monomeric C-reactive protein in patients with myocardial infarction. 96:64-72. 2012
- Microparticles: major transport vehicles for distinct microRNAs in circulation. 93:633-644. 2012
- Enhanced cardiac PI3Kα signalling mitigates arrhythmogenic electrical remodelling in pathological hypertrophy and heart failure. 93:252-262. 2012
- TLR2 ligands induce cardioprotection against ischaemia/reperfusion injury through a PI3K/Akt-dependent mechanism. 87:694-703. 2010
- Lipopolysaccharide-induced myocardial protection against ischaemia/reperfusion injury is mediated through a PI3K/Akt-dependent mechanism. 78:546-553. 2008
- Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. 77:178-187. 2008
- Adventitial application of the NADPH oxidase inhibitor apocynin in vivo reduces neointima formation and endothelial dysfunction in rabbits. 75:710-718. 2007
- Nitric oxide suppresses NADPH oxidase-dependent superoxide production by S-nitrosylation in human endothelial cells. 75:349-358. 2007
- Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes. 72:112-123. 2006
- Corrigendum to: The RyR2 central domain peptide DPc10 lowers the threshold for spontaneous Ca2+ release in permeabilized cardiomyocytes [Cardiovascular Research 70 (2006) 475–485]. 71:606-606. 2006
- The RyR2 central domain peptide DPc10 lowers the threshold for spontaneous Ca2+ release in permeabilized cardiomyocytes. 70:475-485. 2006
- C-type natriuretic peptide (CNP) suppresses plasminogen activator inhibitor-1 (PAI-1) in vivo. 66:574-582. 2005
- The contribution of Nox4 to NADPH oxidase activity in mouse vascular smooth muscle. 65:495-504. 2005
- Cardiac ischemia causes inhibition of the Na/K ATPase by a labile cytosolic compound whose production is linked to oxidant stress. 57:1044-1051. 2003
- Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP. 57:515-522. 2003
- Cholinergic neurogenic vasodilatation is mediated by nitric oxide in the dog hindlimb. 28:542-547. 1994
- A digital computer model of the vectorcardiogram: A design permitting the simulating of abnormal conduction in the ventricles. 7:849-858. 1973
- The controversial role of dairy products in cardiovascular health: time to pass from epidemiology to basic research 2018
- Poster session 1 2012
- Prime time viewing of the ischaemic heart: new technologies allow imaging and flow assessment of the microvasculature in the beating heart. 115. 2019
- What matters in Cardiovascular Research? Scientific discovery driving clinical delivery. 114:1565-1568. 2018